MAP2K7 and hypophosphatemia: A 2-year-old with HRAS-related Mosaic RASopathy complicated by rhabdomyosarcoma, and hypophosphatemia showed marked improvement with MEK inhibitor trametinib, highlighting its potential as targeted treatment.